NCS Multistage Q2 2025 Earnings Call Transcript

Quartr
Provided by Quartr
August 1, 2025

Key Takeaways

  • Positive Sentiment: Q2 revenue of $36.5 million surpassed the high end of guidance by over $7 million, with adjusted EBITDA improving to $2.2 million.
  • Positive Sentiment: Year-to-date 2025 revenue reached $86 million (+18% YoY), driven by a 27% increase in Canadian revenue to $56 million that outpaced rig‐count growth.
  • Positive Sentiment: The acquisition of ResMetrix for up to $7.15 million expands NCS’s tracer diagnostics portfolio, aiming to build the leading global tracer services business.
  • Negative Sentiment: Adjusted gross margin declined to 36% from 40%, primarily due to a less favorable mix of products and the timing of tracer projects.
  • Negative Sentiment: Full-year 2025 guidance remains a wide range—$172 million–$181 million revenue and $22 million–$25.5 million EBITDA—reflecting caution around lower rig counts and market volatility.
AI Generated. May Contain Errors.
Earnings Conference Call
NCS Multistage Q2 2025
00:00 / 00:00

There are 6 speakers on the call.

Operator

Good day and thank you for standing by. Welcome to the Second Quarter twenty twenty five NCS Multistage Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone.

Operator

You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Mike Morrison, Chief Financial Officer. Please go ahead.

Speaker 1

Katie, and thank you for joining the NCS MultiStage Second Quarter twenty twenty five Conference Call. Our call today will be led by our CEO, Ryan Hummer, and I will also provide comments. I want to remind listeners that some of today's comments include forward looking statements such as our financial guidance and comments regarding our future expectations for financial results and business operations. These statements are subject to many risks and uncertainties that could cause our actual results to differ materially from any expectation expressed herein. Please refer to our most recent annual report on Form 10 ks and our latest SEC filings for risk factors and cautions regarding forward looking statements.

Speaker 1

Our comments today, as well as the results of operations included in our earnings release contain the following non GAAP financial measures: Adjusted EBITDA, adjusted gross profit, adjusted gross margin, and free cash flow less distributions to non controlling interest. These non GAAP measures and reconciliations to the most comparable GAAP financial measures are provided in our second quarter earnings release, which can be found on our website, ncsmultistage.com. I will now turn the call over to Ryan.

Speaker 2

Thank you, Mike, and welcome to our investors, analysts and employees who are joining our second quarter twenty twenty five earnings conference call. Mike will cover our quarterly financial results in more detail a bit later. I'll speak about a few highlights for the quarter and for the 2025, and we'll also discuss the acquisition of ResMetrics, which we announced yesterday. NCS is off to a strong start in 2025. Building on solid first quarter results, our second quarter revenue of $36,000,000 exceeded the high end of our guided range by more than $7,000,000 reflecting better than expected performance in each geography.

Speaker 2

Our performance in Canada was the highlight for us again this quarter. Our revenue for the 2025 was over $86,000,000 which is 18% or nearly $13,000,000 higher than the 2024, anchored again by strong performance in Canada. Our adjusted EBITDA of $2,200,000 for the 2025 exceeded our guided range of negative $2,000,000 to breakeven and represented a year over year improvement of $1,300,000 Our adjusted EBITDA of $10,400,000 for the 2025 represents an increase of $3,400,000 or 49% compared to the 2024. So to reiterate, NCS has had a strong 2025. In prior earnings calls, I've referenced NCS' core strategies for creating value for our stakeholders.

Speaker 2

Slide 16 of our investor presentation helps to illustrate our strategy with examples of our progress. The first core strategy is to build upon our leading market positions. Our progress towards this goal continues to be reflected in our year to date results in Canada. Our revenue in Canada for the 2025 was $56,000,000 increasing 27% compared to the same period in 02/2004, far outpacing changes in the average Canadian land rig count. This favorable performance was most prevalent for our fracturing systems product line, as more operators in the Montney have adopted our single point entry frac technology and have experienced strong production results and increased operational flexibility.

Speaker 2

We've also increased sales of composite plugs in Canada, again with customers in the Montney and the Duvernay play. Many of our customers utilizing plug and perf completions will strategically plan ahead to work through spring breakup, which has partially mitigated the typical seasonality of our Canadian business. Our second core strategy is to capitalize on international and offshore opportunities. We're seeking to build on the success we achieved in 2024, a year in which international revenue reached 10% of total revenue, an important milestone for NCS. We expect continued success with customers in the North Sea, as our growing customer base and operational track record have positioned us for long term growth in that market.

Speaker 2

We've had multiple successful North Sea operations this year, and we expect to be busy in the region for the foreseeable future. We expect to deliver or install sleeves or to perform service walk for wells with sleeves that are already installed for seven North Sea customers in 2025. That's an increase compared to five customers in 2024 and from only two customers in the region in 2022. In 2024, we signed a commercial purchase agreement with a customer in The Middle East, and we're encouraged by the pace of adoption of our well construction products in unconventional wells in the region. The increase in well construction sales has partially offset timing delays associated with tracer diagnostics projects in the region, as service companies await the award of tenders for completion services, including pressure pumping.

Speaker 2

We're also actively working with one of our Middle East regional partners to transition away from radioactive tracing to chemical tracing in the region. Third core strategy for NCS is to commercialize innovative solutions to complex customer challenges. We have internal objectives this year that are tied to field trials for new products and for successfully entering new markets and regions. I touched on several of these on the last call, and will provide an update on a few notable items. So during the second quarter, we successfully ran our first seven inches sliding sleeve and service tool for a remedial cementing application.

Speaker 2

The customer was pleased with the results and has subsequently ordered additional tools. Repeat Precision has experienced strong uptake of its new offerings, particularly the StageSaver composite frac plug in The United States and in Canada. The Stage Saver is designed to de risk certain issues that can arise during simul frac, or I guess trimul frac and other operations, which includes screen outs and perforating gun misfires. We have several other products and services for which we expect field trials to begin in the second half of the year, and I'm looking forward to discussing these products and services on future calls. I'll now spend a few minutes reviewing the strategic acquisition that we announced yesterday.

Speaker 2

I'm excited to announce the acquisition of ResMetrix and to welcome the ResMetrix team to NCS. ResMetrix is a provider of tracer diagnostics technologies and services, and has built an excellent business that we believe is highly complementary with our current tracer diagnostics product line. ResMetrix success has resulted from its end to end scientific approach to enable more quantitative results from cost effective tracer diagnostic studies. Through precise chemical manufacturing, tracer injection and sampling programs, and robust chemical portfolio performance testing, ResMedrix has built a growing and profitable business, with trailing twelve month unaudited revenue through June 2025 of over $10,000,000 generating an EBITDA margin of over 30. ResMetrix business complements our existing tracer diagnostics product line in many ways.

Speaker 2

From a product and service offering perspective, ResMetrix provides NCS with a liquid oil tracer offering, which we compare with our existing products to provide a combined offering of both liquid and particulate tracers for oil and for water, natural gas tracers, and radioactive tracer services. In addition, the ResMedrix team has additional expertise in designing and executing tracer diagnostics projects for enhanced oil recovery applications, such as water floods, and for high temperature applications, which we believe will be growing markets over time. Both NCS and have unique tracer portfolios, and in time we believe that our customers will be better served with a larger combined, high performance chemical tracer portfolio, which can enhance the value of tracer diagnostics projects. Although NCS and ResMedrix have historically competed head to head for tracer work in The US, our customer bases have limited overlap, and we believe that each of our respective current customer bases will benefit from the broader service offering of the combined portfolio. In addition, with a combined larger customer base and geographic footprint, new service and product developments in this product line will be more scalable and impactful to NCS.

Speaker 2

Internationally, the addition of ResMetrics expands our presence in The Middle East into The UAE and Kuwait through strategic partnerships with service companies operating in the region. We've been very impressed with the team at ResMedrix while evaluating the transaction and planning the upcoming integration. The focus of this transaction is to create the leading global tracer diagnostics business and to establish a strong platform for product and service development around reservoir diagnostics. I'm confident that we can achieve this goal through the efforts of the NCS and ResMetrix combined team. We'll be methodical in our integration, keeping the voice of the customer in mind as we identify and implement the best practices from ResMetrics and NCS across all of the relevant workflows, many of which will take some time to validate in laboratory.

Speaker 2

While the transaction is not predicated on cost synergies, we believe that in time we will benefit from the implementation of these best practices as we seek to optimize chemical usage, realize economies of scale, and better utilize the skill sets of our employees. In past calls, I've referred to our balance sheet as a strategic asset, and this transaction is a great example of that. Our strong balance sheet and capital light business model generates free cash flow through industry cycles. We're utilizing cash on hand to fund this acquisition, while maintaining a net cash balance and robust liquidity. Deploying cash on hand for the strategic acquisition of a growing and profitable business enables us to improve our return on capital, and we believe positions us to create additional value for our shareholders over time.

Speaker 2

As the North American E and P business matures and our customers consolidate to benefit from economies of scale, we believe that oilfield services providers in the industry will need to do the same, engaging in strategic horizontal combinations like this one. At NCS, we believe that the capabilities of our people, our infrastructure, and the breadth of our product lines operating in strategic geographies, along with our strong balance sheet, positions us well to supplement our organic growth strategy with complementary transactions like the Rasmetrics acquisition over time. Mike will now review our results for the second quarter and our guidance for the third quarter.

Speaker 1

Thank you, Ryan. As reported in yesterday's earnings release, our second quarter revenues were $36,500,000 our highest second quarter revenue results since 2019, representing a year over year improvement of 23%. Our Canada revenues improved by 49%, driven by an increase in fracturing system sales. Our US revenues improved by 15%, also reflecting an increase in fracturing system sales, as well as higher frac plug sales at Repeat Precision. Our international revenues decreased by 17%, primarily due to the timing of tracer diagnostic projects in The Middle East, partially offset by an increase in the North Sea fracturing system cells and an increase in well construction revenues in The Middle East.

Speaker 1

Sequentially, our revenues for the second quarter decreased 27%, reflecting the normal seasonal decline in Canada resulting from spring breakup, offset somewhat by favorable increases for both The U. S. And our international operations. Our adjusted gross profit, defined as total revenues less total cost of sales excluding depreciation and amortization expense, was $13,000,000 for the 2025, or an adjusted gross margin of 36%, down compared to our adjusted gross margin of 40% from one year ago. The decrease in our adjusted gross margin was primarily due to the mix of products sold and services provided for the respective periods.

Speaker 1

Selling, general and administrative costs were $13,600,000 for the 2025, down by $1,200,000 compared to the same period last year. Other income was $1,600,000 for the 2025 and related primarily to royalty income from licenses of our intellectual property and to a lesser extent, the gain on sale of fixed assets. We recorded an income tax benefit of 1,000,000 for the 2025. Of this amount, a tax benefit of 1,400,000.0 resulted from the reversal of a portion of our previously recorded valuation allowance on Canadian deferred tax assets, which was no longer deemed appropriate as these deferred tax assets are expected to be fully realized. Our net income for the second quarter was $900,000 or diluted earnings per share of $0.34 an improvement compared to the second quarter net loss of $3,100,000 or a loss per share of 1.21 in the prior year.

Speaker 1

Our adjusted EBITDA was $2,200,000 an improvement compared to $900,000 for the 2024. Now turning to the balance sheet and an overview of our cash purchase of ResMedrix. As of June 30, cash on hand was $25,400,000 and total debt was $7,700,000 which consisted entirely of finance lease obligations, resulting in a positive net cash position of $17,700,000 The borrowing base under our undrawn ABL facility was $17,200,000 and our total liquidity was approximately $42,500,000 including cash and availability under our revolving credit facility. The total purchase price for ResMetrics is up to a maximum cash amount of $7,150,000 subject to a working capital adjustment. At yesterday's closing, we paid $5,900,000 The purchase agreement includes an earn out component of up to $1,250,000 that would be paid in the 2026.

Speaker 1

After yesterday's closing, our net cash position remains above $10,000,000 and our liquidity is approximately $36,000,000 including cash and the availability under our undrawn revolver. Now turning to a few points of guidance for the third quarter. To ease the comparison to our prior results, I've excluded res metrics from these estimates. However, Ryan will provide guidance separately on the expected contribution of ResMetrics for the remainder of 2025. We currently expect third quarter total revenue in the range of $42,000,000 to 46,000,000 We expect Canadian revenue in the range of $25,000,000 to $27,000,000 U.

Speaker 1

Revenue of 12,000,000 to $13,000,000 and international revenue of 5,000,000 to $6,000,000 We expect our adjusted gross margin to range from 40% to 42% and our adjusted EBITDA to range from $5,500,000 to $7,000,000 Our third quarter depreciation and amortization expense is projected to be approximately 1,400,000.0 With that, I'll hand it back to Ryan to discuss our 2025 full year guidance and for closing remarks.

Speaker 2

Thank you, Mike. We're making only slight adjustments to our full year guidance for 2025. I'll provide you with an apples to apples update for our guidance and then provide our expectation for the contribution of ResMetrics for the last five months of the year. While NCS performed well during the 2025, we are a bit more cautious regarding the second half of the year, as market and industry conditions have continued to deteriorate, including a further decline in The U. S.

Speaker 2

Rig count, a slower than normal rig count recovery in Canada following spring breakup, the potential for an oversupplied oil market due to an increase in OPEC plus oil supply, and ongoing uncertainties related to tariffs and trade. Therefore, we're maintaining a wider than normal range for our annual operating guidance. So given that backdrop, we are modestly increasing our expectation for annual revenue to 168,000,000 to $176,000,000 in 2025, which represents year over year growth of 6% at the midpoint, led by Canada and also by product sales at Repeat Precision in The U. S. We've modified our adjusted EBITDA range to 21,000,000 to $24,000,000 a modest increase to the low end with a midpoint of $22,500,000 We continue to expect free cash flow after distributions to our non controlling interest and excluding the cash paid for ResMetrix of $7,000,000 to $11,000,000 this year, further strengthening our robust balance sheet.

Speaker 2

As a reminder, our free cash flow generation is typically strongest during the fourth quarter of the year. Finally, we expect that ResMetrics will contribute an additional 4,000,000 to $5,000,000 of revenue and 1,000,000 to $1,500,000 of adjusted EBITDA for the last five months of 2025. That would bring our combined revenue guidance range for the year to $172,000,000 to $181,000,000 and our combined adjusted EBITDA guidance to $22,000,000 to $25,500,000 for the year. Before we open the call up for questions, I'll close with a couple of brief comments. We continue to deliver on the core strategies that we implemented in 2025 that are designed to generate value for our stakeholders through organic growth and technology introductions.

Speaker 2

We have the infrastructure in place to support revenue growth in each of our geographic markets, providing leverage to grow future earnings. We continue to benefit from the successful introduction of new solutions that meet the needs of our customers, adding to our portfolio and expanding our addressable market. Our recent acquisition of ResMedrix complements our core strategies for organic growth. With the acquisition, we bolstered our global market position in Tracer Diagnostics, expanding our service offerings, adding operational scale, and enhancing our position in the strategic Middle East Region. We maintain a strong balance sheet and liquidity position with post acquisition total liquidity, including availability under our revolver of approximately $36,000,000 In addition, we expect to increase our cash balance by generating positive free cash flow in 2025, providing us with incremental financial and strategic flexibility.

Speaker 2

This strong balance sheet and confidence in continued free cash flow generation enabled us to fund the strategic acquisition of ResMetrix with cash, a transaction that we expect to be accretive to earnings and improve our return on capital employed. With that, we welcome any questions.

Operator

Thank And our first question comes from Dave Storms of Stonegate. Your line is open.

Speaker 3

Morning.

Speaker 2

Want to start

Speaker 4

with the ResMetrics acquisition a little bit more. You mentioned there's not a lot of overlap between ResMetrics customers and Tracer Diagnostics customers. I guess when we project this out a year or so, what kind of opportunities do you see for cross selling going forward via either domestically or internationally? How do you envision that playing out?

Speaker 2

Yeah, it's a great question, Dave. So yeah, we do serve a pretty distinct set of customers, especially in The US. And when we talked earlier, we discussed where we have some gaps in our product line where ResMetrics service offering fills in and where we have some unique attributes, whether that be on the radioactive tracers. And then also some field deployed solutions that we think we bring to the combination and being able to take those new technologies and bring them out to a broader customer set is certainly something that's really compelling with respect to the deal. We do think there will be some revenue synergy opportunities.

Speaker 2

We think about ResMedrix on a trailing twelve month basis, generating about 10,000,000 of revenue. Our tracer diagnostics business was between 15,000,000 and $20,000,000 So on a combined basis between 25,000,000 and $30,000,000 for a trailing twelve month period. And as you look forward, I do think that by bringing that broader service offering to the existing tracer diagnostics customers, we'll be able to continue to take share in that market and also just build the use cases for tracer diagnostics more broadly. So hesitate to put a number on it, but we do think that there should be some revenue synergy opportunities as we move forward.

Speaker 4

That's very helpful. Thank you. And with this acquisition, you mentioned it did open up a couple of new geographies for you. I guess thinking about your international footprint at the company wide level, Are there any regions that you're particularly excited to start targeting? Or is the market uncertainty kind of keeping you more focused on your core competencies, do you think, in the near to medium term?

Speaker 2

Yeah, so it's kind of a combination of geographic and product specific opportunities that we're looking after. Certainly looking to continue the momentum that we have in the North Sea and in The Middle East and the ResMedrix acquisition absolutely helps with broadening our presence in The Middle East. I think another thing that you can think about is most of the success that we've had in the North Sea has been shallow water offshore in general. And the North Sea is not the only market that's applicable offshore for our technology. So we're looking to push into other offshore markets, whether that be Gulf Of America and other operating regions that would leverage the operational success that we've had with our technology offshore.

Speaker 4

That's very helpful. Thank you. And then one more if I could. Just when we're thinking about the guidance and the range that you've given us, I guess, at a high level, what would you need to see either in the macro environment or maybe in your sector specifically that would give you the confidence to maybe tighten that guidance range in Q3? Is it just rig counts?

Speaker 4

Or are there other things that you have your eye on? Anything there would be helpful.

Speaker 2

Yeah, look, I think given the fact that about 60% of our revenue historically has been generated in Canada, we're certainly keeping an eye on the Canadian rig count. In the comments, had mentioned that rig count's a little bit lower coming out of breakup versus last year. The first half of the year, Canadian rig count was pretty flat year over year. If we look today, I think the rig count's in the high 180s. This time last year, it probably would have been two fifteen, two twenty.

Speaker 2

So we're about 10% to 15% below where we were. So as as the customers in Canada continue to bring rigs back and as that gap as far as the rig count relative to next last year narrows, I think we'd get have a little bit more confidence to narrow the range as well.

Speaker 4

That's all very helpful. Thank you for taking my questions and good luck in Q3.

Speaker 1

All right. Thanks, Dave.

Operator

Thank you. And our next question comes from Joshua Jane of Daniel Energy Partners. Your line is open.

Speaker 3

Thanks. Good morning. First one is just on the acquisition. You talked about potential for synergies over time. And I think you highlighted the 30% EBITDA margins.

Speaker 3

Just where do you see the opportunity to get margins to in this business over, let's say, the next couple of years as you scale it?

Speaker 2

Yes, no, great question, Josh. When I think about the synergy opportunity in the business, it really is gonna come down to the adoption of best practices across the two organizations. So while we compete head to head and we effectively do the same thing, right? We qualify chemicals, we build them, we inject them into customers' wells, take samples and produce analysis reports. We both do it in slightly different ways and in ways that we believe our customers value.

Speaker 2

So the next, over the course of the next six months, right, with the voice of the customer in mind, we're gonna identify those best practices. But we do think that within that, whether it comes from the way we prepare samples, the way we calibrate our instruments, that we should be able to reduce our cost of sales through using a smaller amount of chemical or potentially being more strategic about the cost of the chemical that we deploy into the customers' wells. And think that in time that we can generate synergies, whether it be I hesitate to frame it on a margin percentage on the ResMetrics business because the opportunities will come across the broader combined portfolio. But do think there's a potential for somewhere between 1,000,000 and $2,000,000 over the long run as far as operational synergies that could come through running the businesses together.

Speaker 3

Okay, thanks. And then maybe you could just speak to the mindset of both your Canadian and U. S. Customer base. So we've had a pretty volatile second quarter just from a news and macro and commodity price standpoint, starting with Liberation Day and then just a lot of volatility from both OPEC and a lot of different pockets.

Speaker 3

And is there a case to be made that where we sit today, you highlighted the rig count slower both in The U. S. And Canada on a year over year basis. But is there a case to be made that the customer base is sitting in a better spot now that things have calmed down today versus where we were say ninety to one hundred days ago? And maybe you could just speak to their mindset and sense of urgency today of operators would be great.

Speaker 3

Thank you.

Speaker 2

Yeah, thanks, Josh. I'll do my best there. So, I think specifically in The US, I think you're right, there was a lot of concern post Liberation Day, oil prices fell, uncertainty around trade and tariffs. Oil price has hung in there better than I think most would have expected. But I also believe that the customers are looking at the actions of OPEC plus and just waiting to see if the market really turns into an oversupply situation later this year.

Speaker 2

So I think it's more of a wait and see. I do think that a lot of the oil directed activity from a rig count reduction standpoint has already happened. I think it'll moderate a bit as you move through Q3, but probably some further reductions. And as you move into Q4, it's hard to tell. Obviously, you could run into the situation where you have budget exhaustion and some further rig count decline there.

Speaker 2

But I think the tone is kind of cautiously optimistic. It's worse than feared, but folks are still looking at the fourth quarter and wondering when is that OPEC supply when it hits the market, how will it impact the market? I think in Canada, there was a little bit of a pull forward in activity ahead of some of the tariff fears in Q1 and early Q2. And the Canadian market with breakup has a chance to kind of sit back and reassess their forecasts. You've also seen specific to Canada, the local gas market, AECO, has been really weak lately.

Speaker 2

So some of the gas directed activity has been curtailed. And I think we've heard similar comments from whether it be Trican or Precision Drilling about slower start to Q3, but some general confidence about activity picking up in the latter part of the year. So I think we just echo the comments that some of the other more kind of Canada exposed services companies have expressed over the last few days around that. Understood, thank you very much. I'll turn it back.

Operator

Thank you. And our next question comes from Gautam Fri from Singular Research. Your line is open.

Speaker 5

Good morning, guys. Can you hear me?

Speaker 2

We can. Good morning, Gaushi.

Speaker 5

Good morning. My first question is, given your comments about kind of the traction you're having in Canada, given your outperformance, can you disaggregate on how much growth is coming from new customer wins versus the expanded activity activity with the existing core clients, especially in light of the overall Canadian US rig count?

Speaker 2

Yeah, we'll do my best there. And think even in our investor presentation, slide that I highlighted, 16, shows our Canadian revenue relative to the rig count for the first half of the year. So we're clearly outpacing the underlying activity level that a lot of that has to do, as I mentioned in the prepared comments about the fact that we've grown our customer base in the Montney, which is the most active region in Canada. And for us, the region where customers will run the highest number of sleeves. So the opportunity on a per well basis for us in the Montney is greater than it is in many other regions.

Speaker 2

We've also had some interesting trial opportunities in some other markets that would represent growth initiatives for us. And then at certain other regions in Canada, some of the customers are simply drilling longer laterals or experiencing tighter stage counts or running more sleeves per well. So there are a number of factors that are kind of driving us outperforming the underlying rig count. And we do think that can continue in the second half of the year, maybe that not that same degree of outperformance. But it's also why I think if you unpack the revenue guidance, we're probably flat to down a little bit in the back half of the year versus 2024 with the backdrop of the Canadian rig count currently being 10% to 15% below where it was last year.

Speaker 2

So expectation for continued outperformance relative to the market there. And if the market firms up a bit, we would certainly benefit from it.

Speaker 1

Okay.

Speaker 5

On the margin side, were there any competitive price concessions, product mix or input cost headwinds most responsible? How much pricing power do you believe you can maintain if the softness continues into H2?

Speaker 1

Yes, this is Mike. I think the question was kind of margin, the 36 to the 40 compared to last year, how much that was concessions and the answer to that not really much, if any, kind of as I said in my prepared remarks, was really more the just the mix of products and services. Just in The Middle East, we had a little bit fewer tracer projects during the quarter compared to how we ramped up, you know, one year ago. That's high margin work, so it did have somewhat of an impact. So I think overall, yeah, we we see it as, you know, we can maintain, you know, kinda who we are.

Speaker 5

Okay. And and on the integration of the of the and with the new acquisition, how are the project level profitability payment terms trending for the recent Middle East, North Sea jobs? How do you see that sensitized? Are these margins potential, any execution rates or payment delays? Or how does the integration and the project level profitability will trend in The Middle East?

Speaker 2

Yeah, I'll talk to maybe a little bit overall first. And the North Sea and The Middle East are different markets, I guess, with respect to payment terms, maybe similar with respect to our kind of margin profile that we expect in the markets. Generally, when we participate in projects internationally, we're being brought into those based on technical and technological differentiation that we provide. And we tend to be able to earn a better than average corporate margin as a result. So the work in the North Sea and The Middle East is generally pretty good from a margin standpoint.

Speaker 2

It's a good question with respect to payment terms, and they are different between the two markets. In the North Sea, our customers are some of the best and quickest paying customers in our portfolio. In The Middle East, we tend to operate through local operating partners and that process tends to extend payables a bit as a result. So we need to make sure that we kind of price that working capital drag from operating in the region into the price we charge our customers and the margin that we receive. And we think we do that appropriately.

Speaker 2

But yes, if we were to grow disproportionately in The Middle East, you might see our receivables term out a little bit as a result. But we account for that in the way we scope the projects and price them.

Speaker 5

That's all I have. Thank you, guys.

Speaker 2

Right, appreciate it.

Operator

You. I'm showing no further questions at this time. I'd like to turn it back over to Ryan Hummer for closing remarks.

Speaker 2

All right. Thank you, Didi. So, on behalf of our management team and board, we'd like to thank everyone joining the call today, including our shareholders, analysts, and especially our employees, including the team that just joined us from ResMedrix. I truly appreciate the tremendous work and dedication demonstrated by our team as we implement our long term strategies, and as we welcome and integrate ResMedrix, aligning on best practices within Tracer Diagnostics. We're only as good as our people who continually demonstrate why I believe we have the best team in the industry.

Speaker 2

Our team continues to provide excellent service to our customers while developing new products and services that will enable our customers and NCS to be even more successful. We appreciate everyone's interest in NCS Multistage and look forward to talking again on our next quarterly earnings call.

Operator

This concludes today's conference call. Thank you for participating, and you may now disconnect.

Powered by Quartr